A pilot study on anti-reflux mucoplasty with valve as novel endoscopic therapy for gastroesophageal reflux disease

IF 1.4 Q4 GASTROENTEROLOGY & HEPATOLOGY
DEN open Pub Date : 2025-05-04 DOI:10.1002/deo2.70131
Kazuki Yamamoto, Haruhiro Inoue, Ippei Tanaka, Rei Miyake, Masachika Saino, Kei Ushikubo, Miyuki Iwasaki, Yohei Nishikawa, Satoshi Abiko, Boldbaatar Gantuya, Manabu Onimaru, Mayo Tanabe
{"title":"A pilot study on anti-reflux mucoplasty with valve as novel endoscopic therapy for gastroesophageal reflux disease","authors":"Kazuki Yamamoto,&nbsp;Haruhiro Inoue,&nbsp;Ippei Tanaka,&nbsp;Rei Miyake,&nbsp;Masachika Saino,&nbsp;Kei Ushikubo,&nbsp;Miyuki Iwasaki,&nbsp;Yohei Nishikawa,&nbsp;Satoshi Abiko,&nbsp;Boldbaatar Gantuya,&nbsp;Manabu Onimaru,&nbsp;Mayo Tanabe","doi":"10.1002/deo2.70131","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and aims</h3>\n \n <p>Endoscopic anti-reflux therapies like anti-reflux mucosectomy (ARMS) and anti-reflux mucosal ablation have shown efficacy for gastroesophageal reflux disease (GERD) in systematic reviews and meta-analyses. Anti-reflux mucoplasty (ARM-P), a refinement of ARMS, incorporates immediate closure of the resection site to reduce complications. Recently, anti-reflux mucosal valvuloplasty (ARMV), which employs endoscopic submucosal dissection to create a mucosal valve, was introduced but retains ARMS's limitations, requiring extensive incisions (three-quarters to four-fifths circumference). To address these challenges, we developed anti-reflux mucoplasty with valve (ARM-P/V), integrating ARMV's valvuloplasty with ARM-P's closure technique to improve safety and reduce complications. This pilot study evaluates the safety, feasibility, and efficacy of ARM-P/V.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study reviewed data from patients undergoing ARM-P/V for proton pump inhibitor (PPI)-refractory or PPI-dependent GERD at Showa University Koto Toyosu Hospital, Tokyo, from April to August 2024. Symptom severity and quality of life were assessed using validated questionnaires (GERD-Health Related Quality of Life Questionnaire [GERD-HRQL], GERD Questionnaire [GerdQ], and Frequency Scale for the Symptoms of GERD [FSSG]), comparing pre- and post-treatment scores. PPI discontinuation rates were also analyzed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eighteen patients (mean age 55.4 years) underwent ARM-P/V. Within 3 months, 72.2% (13/18) reduced or discontinued PPI use. GERD-HRQL scores improved from 20.3 to 10.9 (<i>p</i> = 0.004), GerdQ from 10.4 to 6.9 (<i>p</i> &lt; 0.001), and FSSG from 24.0 to 13.2 (<i>p</i> &lt; 0.001). No severe complications (Clavien-Dindo Grade ≥3), delayed bleeding or dysphagia requiring balloon dilation were reported.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>ARM-P/V demonstrates safety, technical feasibility, and short-term efficacy in GERD treatment. As a refinement of ARMV, it offers a promising alternative to current techniques.</p>\n </section>\n </div>","PeriodicalId":93973,"journal":{"name":"DEN open","volume":"6 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/deo2.70131","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DEN open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/deo2.70131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims

Endoscopic anti-reflux therapies like anti-reflux mucosectomy (ARMS) and anti-reflux mucosal ablation have shown efficacy for gastroesophageal reflux disease (GERD) in systematic reviews and meta-analyses. Anti-reflux mucoplasty (ARM-P), a refinement of ARMS, incorporates immediate closure of the resection site to reduce complications. Recently, anti-reflux mucosal valvuloplasty (ARMV), which employs endoscopic submucosal dissection to create a mucosal valve, was introduced but retains ARMS's limitations, requiring extensive incisions (three-quarters to four-fifths circumference). To address these challenges, we developed anti-reflux mucoplasty with valve (ARM-P/V), integrating ARMV's valvuloplasty with ARM-P's closure technique to improve safety and reduce complications. This pilot study evaluates the safety, feasibility, and efficacy of ARM-P/V.

Methods

This retrospective study reviewed data from patients undergoing ARM-P/V for proton pump inhibitor (PPI)-refractory or PPI-dependent GERD at Showa University Koto Toyosu Hospital, Tokyo, from April to August 2024. Symptom severity and quality of life were assessed using validated questionnaires (GERD-Health Related Quality of Life Questionnaire [GERD-HRQL], GERD Questionnaire [GerdQ], and Frequency Scale for the Symptoms of GERD [FSSG]), comparing pre- and post-treatment scores. PPI discontinuation rates were also analyzed.

Results

Eighteen patients (mean age 55.4 years) underwent ARM-P/V. Within 3 months, 72.2% (13/18) reduced or discontinued PPI use. GERD-HRQL scores improved from 20.3 to 10.9 (p = 0.004), GerdQ from 10.4 to 6.9 (p < 0.001), and FSSG from 24.0 to 13.2 (p < 0.001). No severe complications (Clavien-Dindo Grade ≥3), delayed bleeding or dysphagia requiring balloon dilation were reported.

Conclusions

ARM-P/V demonstrates safety, technical feasibility, and short-term efficacy in GERD treatment. As a refinement of ARMV, it offers a promising alternative to current techniques.

Abstract Image

胃食管反流病新型内镜治疗瓣膜抗反流粘膜成形术的初步研究
背景和目的在系统综述和荟萃分析中,内镜下抗反流治疗如抗反流粘膜切除术(ARMS)和抗反流粘膜消融术已经显示出对胃食管反流病(GERD)的疗效。抗反流粘膜成形术(ARM-P)是ARMS的改进,包括立即关闭切除部位以减少并发症。最近,引入了抗反流粘膜瓣膜成形术(ARMV),该方法采用内镜下粘膜剥离来创建粘膜瓣膜,但保留了ARMS的局限性,需要广泛的切口(周长的四分之三到五分之四)。为了应对这些挑战,我们开发了带瓣膜的抗反流粘膜成形术(ARM-P/V),将ARMV的瓣膜成形术与ARM-P的闭合技术相结合,以提高安全性并减少并发症。本初步研究评估了ARM-P/V的安全性、可行性和有效性。方法本回顾性研究回顾了2024年4月至8月在东京昭和大学Koto Toyosu医院接受质子泵抑制剂(PPI)难治性或PPI依赖性GERD的患者的数据。采用有效问卷(GERD-健康相关生活质量问卷[GERD- hrql]、GERD问卷[GerdQ]和GERD症状频率量表[FSSG])评估症状严重程度和生活质量,比较治疗前和治疗后的评分。还分析了PPI停药率。结果18例患者行ARM-P/V手术,平均年龄55.4岁。在3个月内,72.2%(13/18)减少或停止使用PPI。GERD-HRQL评分从20.3提高到10.9 (p = 0.004), GerdQ从10.4提高到6.9 (p <;0.001), FSSG从24.0到13.2 (p <;0.001)。无严重并发症(Clavien-Dindo分级≥3)、迟发性出血或需要球囊扩张的吞咽困难。结论ARM-P/V治疗胃食管反流具有安全性、技术可行性和短期疗效。作为ARMV的改进,它为当前技术提供了一个有希望的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信